Avadel Pharmaceuticals announced leader sponsorship of the American Academy of Sleep Medicine, AASM, Foundation’s 15th Annual Young Investigators Research Forum, YIRF. This will be Avadel’s third year as lead sponsor of the YIRF program, which takes place March-June 2023, with virtual events and in-person events. “At Avadel, we’re passionate about supporting the sleep community, including both people with sleep disorders, as well as scientists advancing sleep research,” said Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs at Avadel. “Our ongoing partnership with the AASM Foundation stems from a communal goal to expand the field of sleep medicine for the benefit of patients. We’re proud to support this vital training program with hopes that future discoveries from these early career investigators will result in new ways to better improve the lives of those with disorder sleep conditions, like narcolepsy.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AVDL:
- Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation’s 2023 Young Investigators Research Forum
- Avadel Pharmaceuticals announces publication of survey data on oxybate
- Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy
- Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
